RS56660B1 - Kompozicije koje sadrže benzodiazepine kratkotrajnog dejstva - Google Patents

Kompozicije koje sadrže benzodiazepine kratkotrajnog dejstva

Info

Publication number
RS56660B1
RS56660B1 RS20171260A RSP20171260A RS56660B1 RS 56660 B1 RS56660 B1 RS 56660B1 RS 20171260 A RS20171260 A RS 20171260A RS P20171260 A RSP20171260 A RS P20171260A RS 56660 B1 RS56660 B1 RS 56660B1
Authority
RS
Serbia
Prior art keywords
composition
lyophilized
dextran
lactose
composition according
Prior art date
Application number
RS20171260A
Other languages
English (en)
Serbian (sr)
Inventor
John Aitken Graham
Alan James Baillie
Kevin Richard Ward
Thomas Peacock
Original Assignee
Paion Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS56660(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Paion Uk Ltd filed Critical Paion Uk Ltd
Publication of RS56660B1 publication Critical patent/RS56660B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20171260A 2012-05-22 2013-05-22 Kompozicije koje sadrže benzodiazepine kratkotrajnog dejstva RS56660B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12168968 2012-05-22
PCT/EP2013/060543 WO2013174883A1 (en) 2012-05-22 2013-05-22 Compositions comprising short-acting benzodiazepines
EP13730128.9A EP2852389B1 (en) 2012-05-22 2013-05-22 Compositions comprising short-acting benzodiazepines

Publications (1)

Publication Number Publication Date
RS56660B1 true RS56660B1 (sr) 2018-03-30

Family

ID=48669863

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20171260A RS56660B1 (sr) 2012-05-22 2013-05-22 Kompozicije koje sadrže benzodiazepine kratkotrajnog dejstva

Country Status (41)

Country Link
US (2) US20150148338A1 (OSRAM)
EP (1) EP2852389B1 (OSRAM)
JP (1) JP6313286B2 (OSRAM)
KR (1) KR102116737B1 (OSRAM)
CN (2) CN108578413A (OSRAM)
AP (1) AP2014008084A0 (OSRAM)
AR (1) AR092008A1 (OSRAM)
AU (1) AU2013265295B2 (OSRAM)
BR (1) BR112014029108B1 (OSRAM)
CA (1) CA2874247C (OSRAM)
CL (1) CL2014003171A1 (OSRAM)
CO (1) CO7151503A2 (OSRAM)
DK (1) DK2852389T3 (OSRAM)
EA (1) EA032119B1 (OSRAM)
EC (1) ECSP14032553A (OSRAM)
ES (1) ES2651389T3 (OSRAM)
FR (1) FR21C1043I2 (OSRAM)
GE (1) GEP20186852B (OSRAM)
HR (1) HRP20171872T1 (OSRAM)
HU (2) HUE037734T2 (OSRAM)
IL (1) IL235789B (OSRAM)
LT (2) LT2852389T (OSRAM)
LU (1) LUC00230I2 (OSRAM)
MA (1) MA37581B1 (OSRAM)
MX (1) MX368854B (OSRAM)
MY (1) MY185117A (OSRAM)
NL (1) NL301130I2 (OSRAM)
NO (2) NO2852389T3 (OSRAM)
NZ (1) NZ702063A (OSRAM)
PE (1) PE20150683A1 (OSRAM)
PH (1) PH12014502608B1 (OSRAM)
PL (1) PL2852389T4 (OSRAM)
PT (1) PT2852389T (OSRAM)
RS (1) RS56660B1 (OSRAM)
SG (1) SG11201407710VA (OSRAM)
SI (1) SI2852389T1 (OSRAM)
TN (1) TN2014000479A1 (OSRAM)
TW (1) TWI590826B (OSRAM)
UA (1) UA115063C2 (OSRAM)
WO (1) WO2013174883A1 (OSRAM)
ZA (1) ZA201408412B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2081921E (pt) 2006-07-10 2010-12-10 Paion Uk Ltd Sais de benzodiazepina de acção curta e suas formas polimórficas
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2015076340A1 (ja) * 2013-11-21 2015-05-28 小野薬品工業株式会社 全身麻酔および／または鎮静のための注射用組成物
AU2015214665B2 (en) 2014-02-10 2020-04-23 Biolumic Limited Improvements in and relating to controlling characteristics of photosynthetic organisms
US10517225B2 (en) 2014-03-14 2019-12-31 Biolumic Limited Method to improve crop yield and/or quality
EP3162804B1 (en) 2014-07-23 2019-10-09 Jiangsu Nhwaluokang Pharmaceutical Research and Development Co., Ltd. New benzodiazepine derivative and use thereof
CN107105625A (zh) 2014-09-17 2017-08-29 拜欧卢米克有限公司 种子处理的方法及所得产物
CN105726495B (zh) * 2014-12-12 2019-03-29 宜昌人福药业有限责任公司 一种注射用短效苯并二氮杂卓盐药物组合物及其制备方法
CN107198691A (zh) * 2016-03-17 2017-09-26 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
EP3442539B1 (en) 2016-04-14 2025-04-09 Paion UK Limited Orally inhaled and nasal benzodiazepines
WO2017198224A1 (zh) * 2016-05-20 2017-11-23 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
BR112019003577A2 (pt) 2016-08-22 2019-05-21 Biolumic Ltd métodos de tratamento da semente e produtos resultantes
CN108503644B (zh) 2016-12-09 2019-06-14 成都倍特药业有限公司 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途
AU2018293468A1 (en) 2017-06-29 2020-01-30 Biolumic Limited Method to improve crop yield and/or quality
EP3714884A1 (en) 2019-03-27 2020-09-30 Paion UK Limited Medical uses for benzodiazepines with a particular eeg pattern
CN112209932B (zh) * 2019-07-12 2023-03-24 成都倍特药业股份有限公司 一种化合物氢溴酸盐的新固体形态及其制备方法和用途
ES2803099B2 (es) * 2019-07-22 2021-11-08 Moehs Iberica Sl Procedimiento de obtención de besilato de remimazolam amorfo
CN114478535B (zh) * 2020-10-23 2024-02-09 成都苑东生物制药股份有限公司 一种苯磺酸瑞马唑仑ii晶型的制备方法
CN112462015B (zh) * 2020-11-18 2022-07-12 海南倍特药业有限公司 一种氢溴酸瑞马唑仑细菌内毒素的检测方法
CN114624351B (zh) * 2020-12-14 2024-04-09 宜昌人福药业有限责任公司 苯磺酸瑞马唑仑原料药中(r)-(-)-1-氨基-2-丙醇残留的分析方法
CN120302962A (zh) * 2022-12-16 2025-07-11 Lts罗曼治疗系统股份公司 含有瑞马唑仑的口腔粘膜递送系统
WO2024251275A1 (zh) * 2023-06-09 2024-12-12 成都麻沸散医药科技有限公司 一种氮杂*类化合物及其组合物和应用
WO2025052259A1 (en) 2023-09-05 2025-03-13 Reena Patel Ready to use compositions of remimazolam

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520877A (en) * 1967-10-02 1970-07-21 Hoffmann La Roche 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
ATE203026T1 (de) 1995-01-06 2001-07-15 Hoffmann La Roche Hydroxymethyl-imidazodiazepine und deren ester
AU4382896A (en) 1995-02-02 1996-08-21 F. Hoffmann-La Roche Ag Acetylimidazobenzodiazepines
JPH0971533A (ja) * 1995-06-30 1997-03-18 Takeda Chem Ind Ltd 凍結乾燥製剤
US7160880B1 (en) * 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
GB9911152D0 (en) * 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1161949A1 (en) * 2000-06-09 2001-12-12 Warner-Lambert Company Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
EP2353590A1 (en) * 2005-02-15 2011-08-10 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
GB0613693D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
PT2081921E (pt) * 2006-07-10 2010-12-10 Paion Uk Ltd Sais de benzodiazepina de acção curta e suas formas polimórficas
GB0613692D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
ES2654423T3 (es) * 2009-11-05 2018-02-13 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiacepina
EP2450039A1 (en) * 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
CN102964349A (zh) * 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途

Also Published As

Publication number Publication date
ZA201408412B (en) 2016-09-28
CO7151503A2 (es) 2014-12-29
EP2852389B1 (en) 2017-10-18
AU2013265295A1 (en) 2015-01-22
LTC2852389I2 (OSRAM) 2024-11-25
TN2014000479A1 (en) 2016-03-30
CA2874247C (en) 2020-07-28
PH12014502608B1 (en) 2019-11-27
LTPA2021521I1 (OSRAM) 2021-10-11
TW201400119A (zh) 2014-01-01
IL235789B (en) 2019-07-31
HK1208164A1 (en) 2016-02-26
KR102116737B1 (ko) 2020-05-29
FR21C1043I2 (fr) 2022-10-07
SI2852389T1 (en) 2018-02-28
CN108578413A (zh) 2018-09-28
CN104968348B (zh) 2018-04-17
PL2852389T4 (pl) 2022-02-21
AP2014008084A0 (en) 2014-11-30
GEP20186852B (en) 2018-05-25
NL301130I2 (nl) 2021-10-25
MY185117A (en) 2021-04-30
BR112014029108A2 (pt) 2017-06-27
LT2852389T (lt) 2017-12-27
EP2852389A1 (en) 2015-04-01
US20150148338A1 (en) 2015-05-28
CA2874247A1 (en) 2013-11-28
WO2013174883A1 (en) 2013-11-28
CL2014003171A1 (es) 2015-06-19
JP2015517552A (ja) 2015-06-22
JP6313286B2 (ja) 2018-04-18
FR21C1043I1 (OSRAM) 2021-11-19
MX2014014225A (es) 2015-06-17
MA37581B1 (fr) 2016-07-29
AR092008A1 (es) 2015-03-18
IL235789A0 (en) 2015-01-29
PT2852389T (pt) 2017-12-13
AU2013265295B2 (en) 2017-08-31
SG11201407710VA (en) 2015-01-29
US20220040198A1 (en) 2022-02-10
PL2852389T3 (pl) 2018-02-28
MX368854B (es) 2019-10-18
PH12014502608A1 (en) 2015-01-21
EA201492160A1 (ru) 2015-10-30
NO2852389T3 (OSRAM) 2018-03-17
KR20150009601A (ko) 2015-01-26
NO2021041I1 (no) 2021-09-20
LUC00230I2 (OSRAM) 2022-10-07
TWI590826B (zh) 2017-07-11
ECSP14032553A (es) 2018-11-30
EA032119B1 (ru) 2019-04-30
UA115063C2 (uk) 2017-09-11
PE20150683A1 (es) 2015-06-03
HUE037734T2 (hu) 2018-09-28
HUS2100040I1 (hu) 2021-10-28
HRP20171872T1 (hr) 2018-02-23
DK2852389T3 (en) 2017-12-18
NZ702063A (en) 2016-11-25
NL301130I1 (OSRAM) 2021-09-22
CN104968348A (zh) 2015-10-07
BR112014029108B1 (pt) 2022-02-08
ES2651389T3 (es) 2018-01-26
MA20150233A1 (fr) 2015-07-31

Similar Documents

Publication Publication Date Title
RS56660B1 (sr) Kompozicije koje sadrže benzodiazepine kratkotrajnog dejstva
JP5536753B2 (ja) ベンダムスチン塩酸塩の新規固体形態
JP5380549B2 (ja) ボリコナゾール含有の薬物製剤及びその調製方法
RU2685236C2 (ru) Вдыхаемые частицы, содержащие тиотропий
BRPI0715113A2 (pt) formulaÇço de caspofungina
JP2017519727A (ja) チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法
CN106924172B (zh) 一种石杉碱甲溶致液晶制剂及其制备方法
Liang et al. In situ hexagonal liquid crystal for intra-articular delivery of sinomenine hydrochloride
Liu et al. Preparation, Characterization and Evaluation of Nintedanib Amorphous Solid Dispersions with Enhanced Oral Bioavailability
Karimi et al. Preparation and characterization of injectable in-situ forming gel based on lipid liquid crystal for one month delivery of aripiprazole: In-vitro and in-vivo evaluations in rats
CN108289897B (zh) 一种瑞马唑仑的药物组合物
US9308174B2 (en) Lyophilized formulations of bendamustine hydrochloride
EP2730575B1 (en) Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof
HK1208164B (en) Compositions comprising short-acting benzodiazepines
CN102657646B (zh) 一种药物组合物及其制剂
OA20108A (en) Compositions Comprising Short-Acting Benzodiazepines.
CN111100122A (zh) 左旋四氢帕马丁新化合物
HK1192231B (en) Crystal form i of salt of a dipeptidyl peptidase-iv inhibitor and preparation method and use thereof